Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate whether giving prophylactic metoprolol
prior to and during anthracycline or trastuzumab therapy will decrease the incidence of
anthracycline-induced cardiomyopathy. Patients are randomized to receive metoprolol or no
treatment prior to anthracycline or trastuzumab treatment. The ejection fraction, as measured
by nuclear ventriculography is measured before and after treatment.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore